Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen
Jazz Pharmaceuticals is teaming up with ImmunoGen on a slate of armed antibodies.
Jazz $JAZZ will pay $175 million — $75 million upfront and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
